Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD123 modulators(Interleukin-3 receptor subunit alpha modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators) |
Therapeutic Areas |
Active Indication |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Leukemia | Phase 2 | FR | 24 Oct 2018 | |
Leukemia | Phase 2 | US | 24 Oct 2018 | |
Acute Myeloid Leukemia | Phase 2 | - | - | |
Lymphoid Leukemia | Phase 2 | - | - | |
Myelodysplastic Syndromes | Phase 2 | - | - | |
High Risk Myelodysplastic Syndrome | Preclinical | FR | 24 Oct 2018 | |
Pre B-cell acute lymphoblastic leukemia | Preclinical | FR | 24 Oct 2018 | |
Pre B-cell acute lymphoblastic leukemia | Preclinical | US | 24 Oct 2018 | |
Refractory acute myeloid leukemia | Preclinical | US | 24 Oct 2018 | |
Refractory acute myeloid leukemia | Preclinical | FR | 24 Oct 2018 |
Phase 1/2 | 7 | ihvptzxrsb(ezvtytsyjx) = jyvyjmzidr sxbipzkoqq (fqbfrgyrel, bvlcsdaael - ddrrbgftkk) View more | - | 07 Apr 2022 |